Investors High Interest in Novimmune’s NI-0501 for Special Orphan Disease

1
Investors High Interest in Novimmunes NI-0501
for Special Orphan Disease
2

• Swiss biotech, Novimmunes lead compound- NI-0501
  being developed for treatment of severe
  hyperinflammatory disease, hemophagocytic
  lymphohistiocytosis (HLH) has gained a firm faith
  of the investors.

3

• Novimmune secured another 31 million funding
  this year. Earlier in January, Novimmune raised a
  hefty amount of 30 million from the existing
  investors. With this the company reached the sum
  of around 61 million in just five months.

4

• In this journey of 18 years, Novimmune has raised
  a handsome amount of around 275 million in its
  fundraising rounds.
• With these entire eye popping data, do not forget
  the key driver behind all the funding- NI-0501.
  It is the first treatment being developed for
  HLH.

5

• It received Breakthrough Therapy designation from
  FDA in March.
• As NI-0501 advances with promising results in its
  clinical trials, the investors faith on the
  compound shoot up and they show it with some
  significant bid on the company.

6

• NI-0501 is currently in its Phase II/III trial.
  For unhindered progress of the NI-0501 in its
  clinical studies and further development along
  with the other compounds in the pipeline, extra
  financial resources have been allocated by the
  existing shareholders.  

7

• NI-0501 is a fully human monoclonal antibod
• y which targets interferon-gamma (IFN?) for
  inhibition of IFN?-induced inflammation. IFN? is
  a cytokine secreted by cells of the immune system
  for the regulation of the immune functions.

8

• The importance of this cytokine is explicated in
  its ability to inhibit the replication of viruses
  directly. It helps in stimulation as well as
  regulation of other immune responses in the body.

9
Mechanism of the onset of HLH
10

• HLH is a fatal immune system disorder which
  causes uncontrolled proliferation of activated
  lymphocytes and macrophages which leads to
  secretion of severe amount of inflammatory
  cytokines. It is currently an unmet medical
  condition as no drugs have been approved till
  now. The disease generally occurs to children and
  have 50 mortality rate.

11

• Novimmune Chairman and Chief Executive Officer
  Eduard Holdener said The continued strong
  commitment from our shareholders demonstrates the
  confidence they have in our team, our pipeline
  and the future of the Company.

12

• We remain committed to further developing novel
  medicines to provide improved treatment options
  for patients suffering from rare and devastating
  diseases such as HLH, autoimmune and inflammatory
  diseases or cancer.

13

• The orphan disease like HLH needs certain
  limelight to come under the serious consideration
  of the researchers. Novimmunes endeavor towards
  development of NI-0501 for HLH is really
  appreciating. It seems its developmental journey
   will attract many potential investors in the
  coming time.

14

• To Know More Update, Visit Us

http//medgenera.com/